

Concomitant inactivation of *Rb* and *E2f8* in hematopoietic stem cells synergizes to induce severe anemia

Tinghui Hu,¹ Seda Ghazaryan,¹ Chandler Sy,¹ Charles Wiedmeyer,² Victor Chang,^{3,4} and Lizhao Wu¹

¹Department of Microbiology and Molecular Genetics, New Jersey Medical School—University Hospital Cancer Center, University of Medicine and Dentistry of New Jersey, Newark, NJ; ²Veterinary Medical Diagnostic Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, MO; ³Section of Hematology Oncology, VA New Jersey Health Care System, East Orange, NJ; and ⁴Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ

The retinoblastoma (*Rb*) tumor suppressor plays important roles in regulating hematopoiesis, particularly erythropoiesis. In an effort to understand whether *Rb* function can be mediated by E2F transcription factors in a BM-derived hematopoietic system in mice, we uncovered a functional synergy between *Rb* and E2F8 to promote erythropoiesis and to prevent anemia. Specifically, whereas *Mx1-Cre*-mediated inactivation of *Rb* or *E2f8* in hematopoietic stem cells only led to mild erythropoietic defects, concomi-

tant inactivation of both genes resulted in marked ineffective erythropoiesis and mild hemolysis, leading to severe anemia despite the presence of enhanced extramedullary erythropoiesis. Interestingly, although ineffective erythropoiesis was already present in the *Rb*^{ΔΔ} mice and exacerbated in the *Rb*^{ΔΔ};*E2f8*^{ΔΔ} mice, hemolysis was exclusively manifested in the double-knockout mice. Using an adoptive transfer system and an erythroid-specific knockout system, we have shown that the synergy of *Rb* and *E2f8* defi-

ciency in triggering severe anemia is intrinsic to the erythroid lineage. Surprisingly, concomitant inactivation of *Rb* and *E2f7*, a close family member of *E2f8*, did not substantially worsen the erythropoietic defect resulted from *Rb* deficiency. The results of the present study reveal the specificity of E2F8 in mediating *Rb* function in erythropoiesis and suggest critical and overlapping roles of *Rb* and *E2f8* in maintaining normal erythropoiesis and in preventing hemolysis. (*Blood*. 2012;119(19):4532-4542)

Introduction

The role of the retinoblastoma (*Rb*) tumor suppressor in embryonic erythropoiesis was initially recognized when *Rb*-knockout embryos were analyzed.¹⁻³ These embryos develop anemia with increased immature, nucleated RBCs. Further investigations using conditional knockout approaches, chimeric approaches, or in vitro assays led to controversy about how *Rb* controls hematopoiesis.^{4,5} The main controversy is centered on the cell-autonomous versus non-cell-autonomous action of *Rb* in the control of hematopoiesis. Whereas the non-cell-autonomous role of *Rb* in the control of hematopoiesis has been established in the placenta, fetal liver macrophages, and the BM niche, *Rb* plays a cell-autonomous role in stress erythropoiesis and in an in vitro erythroid-differentiation system.⁶⁻¹¹ More recently, an erythroid-specific role of *Rb* in postnatal erythropoiesis has been identified.¹²

The role of *Rb* in the control of adult hematopoiesis has been established recently using conditional knockout mouse models. Inactivation of *Rb* specifically in hematopoietic stem cells (HSCs) led to a mild anemia, moderate splenomegaly, abnormal expansion of erythroblasts in the spleen, myeloproliferation, and suppression of B lymphopoiesis in the BM.^{7,10} In addition, using an erythroid-specific conditional knockout system, Sankaran et al demonstrated that *Rb* promotes adult erythropoiesis intrinsically by coupling cell-cycle exit with mitochondrial biogenesis.¹²

Previous studies have documented important roles of E2F transcription factors in mediating *Rb* function.^{13,14} In quiescent cells, *Rb* binds and inhibits E2Fs, preventing E2F-mediated

transcriptional activation of genes required for S-phase entry and cell-cycle progression. After mitogenic signaling, quiescent cells relay a series of signaling transduction cascades that involve the activation of cyclin-dependent kinases and the phosphorylation and inactivation of *Rb*, leading to the subsequent release of E2Fs.^{15,16} In mammalian cells, there are 8 known *E2f* genes (*E2f1-8*), with the *E2f3* locus encoding 2 isoforms (3a and 3b).¹⁷ Based on their structural and biochemical properties, E2Fs can be divided into 3 groups. E2F1, E2F2, and E2F3a are considered to be transcriptional activators with activities peaking during the G₁/S transition when released from the *Rb* binding.^{15,16} Conversely, E2F3b, E2F4, and E2F5 are considered to be transcriptional repressors and bind to *Rb* or other pocket proteins (ie, p107 and p130) in quiescent cells to repress target genes. E2F6, E2F7, and E2F8 are also classified as repressors. Unlike E2F1-5, however, they do not have an *Rb* pocket-protein-binding domain.^{17,18} Therefore, their function is thought to be independent of pocket-protein binding. Although E2F6-dependent transcriptional repression is mediated through its ability to recruit the polycomb repressor complex,¹⁹ it is unclear how E2F7 and E2F8 are involved in transcriptional repression. Given the interaction between *Rb* pocket proteins and E2F1-5, it is expected that *Rb* function can be mediated through various E2F activities. Indeed, numerous studies have confirmed that E2Fs are important mediators for *Rb* function.²⁰⁻²⁷ In particular, Dirlam et al showed recently that the terminal differentiation defect in *Rb*-null erythroblasts was suppressed by the loss of E2f2.²⁸ However, it is

Submitted October 25, 2011; accepted March 1, 2012. Prepublished online as *Blood* First Edition paper, March 14, 2012; DOI 10.1182/blood-2011-10-388231.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

unclear whether non-pocket-protein-binding E2Fs, namely E2F6, E2F7, and E2F8, can interact functionally with Rb to mediate its function *in vivo*.

In an effort to understand whether non-pocket-protein-binding E2Fs can mediate Rb function in the hematopoietic system, we uncovered a potent functional synergy between *Rb* loss and *E2f8* loss to induce severe anemia. Mice with HSCs deficient for both *Rb* and *E2f8* suffer from marked ineffective erythropoiesis and mild hemolysis, leading to severe anemia despite the presence of regenerative response and active erythropoiesis. Interestingly, inactivation of *E2f7*, which shares all key functional domains and biochemical features with *E2f8*,¹⁸ does not exacerbate significantly the mild anemia observed in mice with HSCs deficient for *Rb*. Therefore, our data not only demonstrate the functional interaction of Rb and E2F8 to ensure normal erythropoiesis, likely by promoting erythroid terminal differentiation and maintaining erythrocyte membrane integrity, but also suggest possible roles of Rb and E2F8 in preventing hemolysis in humans.

Methods

Mice

All mouse lines used in this study have been described previously.²⁹⁻³² Induction of *Mx1-Cre* was achieved by 3-7 IP injections of 400 μ g of poly(I:C) (Sigma-Aldrich) every other day to 4-week-old mice. Mice were killed 12 weeks after poly(I:C) injection. *EpoR-GFP-Cre*-mediated knock-out mice were killed at 3 months of age. All animal protocols were approved by the institutional animal care and use committee at New Jersey Medical School.

Hematologic parameters

Hematologic parameters for erythroid cells (ie, RBCs, hemoglobin, hematocrit, mean cell volume, and mean cell hemoglobin) were assessed using an automated instrument (Hemavet FS950; Drew Scientific). Hematologic findings were confirmed on peripheral blood smears by a board-certified veterinary pathologist (C.W.). Bilirubin was measured on plasma using an automated method (Olympus AU680; Beckman-Coulter).

FACS

Single-cell suspensions were labeled with surface Abs. Labeled cells were processed with a FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo Version 7.6 software (TreeStar). The following Abs were purchased from eBiosciences or BD Biosciences: CD2 (11-0021-81), CD3 (11-0031-81), CD4 (11-0041-81), CD5 (11-0051-81), CD8 (11-0081-81), CD11b (11-0112-81), CD71 (11-0711-85), B220 (11-0452-85), F4/80 (11-4801-82), Gr1 (11-5931-81), Ter119 (11-5921-81), Flk2 (12-1351-81), Sca 1 (45-5981-82), and c-kit (17-1171-81). For stem cell/progenitor assays, cell suspensions were first stained with lineage Abs (CD2, CD3, CD4, CD5, CD8, CD11b, Gr1, B220, and Ter119), followed by staining with Flk2, Sca 1, and c-kit. Erythroid staging based on CD71 versus forward scatter sorting was performed as described previously³³ using a FACS Vantage cell sorter (BD Biosciences) and DIVA Version 6 (BD Biosciences) or FlowJo Version 7.6 software (TreeStar).

Adoptive transfer and stem/progenitor assays

BM cells were collected from mice that were backcrossed to a FVB background for 2-4 generations. Either 1×10^5 (for colony-forming unit-spleen [CFU-S]) or $1-10 \times 10^6$ (for adoptive transfer) BM cells were injected intravenously into FVB mice that received 13.5 Gy of radiation. For adoptive transfer, mice were killed 3 months after transplantation. For CFU-S assays, mice were killed 8 or 12 days after transplantation and their spleens were removed and fixed in Bouin solution. The hematopoietic colony-forming assay using Methocult M3434 medium (StemCell Technologies) was performed following the directions of the manufacturer.

RBC life span

RBC life span was measured as described previously¹² with minor modifications. RBCs were labeled by IV injection of N-hydroxysuccinimide biotin (Pierce; 25 μ g/g body weight). Approximately 20 μ L of blood was obtained via the retroorbital plexus at 3-day intervals, followed by biotinylation and incubation with FITC-Avidin (Sigma-Aldrich). The percentage of biotinylated RBCs was assessed with the FACSCalibur flow cytometer.

Erythrocyte deformability and osmotic fragility

RBCs (3×10^7) were suspended in 1 mL of 5% polyvinylpyrrolidone (Molecular Weight 360 000; Sigma-Aldrich) at a final viscosity of 29 cP and osmolality of 293 mosmol/kg H₂O. Cell deformability was determined with an ektacytometer (LORCA) by calculating the elongation index.³⁴ Osmotic fragility assay was performed as described previously.³⁵

Cell-cycle distributions and apoptosis

Cell-cycle kinetics were assessed as described previously.¹² Mice were injected intraperitoneally with 5'-bromodeoxyuridine (BrdU) at 150 mg/kg body weight. BM and spleen cells were isolated after 1 hour, fixed, and stained with CD71 and Ter119 Abs. BrdU staining and annexin V staining were performed according to the directions of the manufacturers (559619 and 550474; BD Biosciences).

Erythropoietin concentration measurement

Serum was obtained by centrifuging peripheral blood without any anticoagulant. Serum erythropoietin concentration was determined using a rodent Quantikine Epo Immunoassay kit (MEP00; R&D Systems) following the directions of the manufacturer.

Immunofluorescence staining

Immunofluorescence staining was performed as described previously³⁶ with minor modifications. Permeabilized RBCs were stained with rhodamine-phalloidin (Molecular Probes) and counterstained with SYTOX Green (Molecular Probes) to exclude reticulocytes and leukocytes for quantifications.

Statistical analysis

Values are presented as means \pm SD. Statistical significance was determined by Student *t* test with a significance threshold of $P = .05$.

Results

Concomitant inactivation of *Rb* and *E2f8* results in severe anemia

To determine whether E2F7 and E2F8 can mediate Rb function, we inactivated *Rb*, *E2f7*, and *E2f8* in HSCs using an IFN-inducible system with the *Mx1-Cre* allele.³⁰ Semiquantitative PCR confirmed the efficient deletion of *Rb*, *E2f7*, and *E2f8* in whole BM (supplemental Figure 1, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article, and data not shown). Consistent with previous studies,^{7,10} inactivation of *Rb* in HSCs (ie, *Rb* ^{$\Delta\Delta$}) led to mild anemia, characterized by approximately 20% reductions in RBCs, hemoglobin, and hematocrit (Table 1). Surprisingly, despite mild anemia in *Rb* ^{$\Delta\Delta$} mice and slight reductions of RBCs in *E2f8* ^{$\Delta\Delta$} mice, concomitant inactivation of *Rb* and *E2f8* led to severe anemia, with RBCs, hemoglobin, and hematocrit being reduced by approximately 50%. In contrast, concomitant inactivation of *E2f7* did not exacerbate substantially the mild anemia resulted from *Rb* deficiency, suggesting that *E2f8* (but not *E2f7*) plays a predominant role in mediating *Rb* function in

Table 1. Hematological and biochemical parameters of peripheral blood

Genotype	<i>Rb^{LoxP/LoxP}</i>	<i>Rb^{Δ/Δ}</i>	<i>E2f8^{Δ/Δ}</i>	<i>Rb^{Δ/Δ}</i>			
				<i>Rb^{Δ/Δ} E2f8^{Δ/Δ}</i>	<i>E2f7^{Δ/Δ} E2f8^{Δ/Δ}</i>	<i>Rb^{Δ/Δ} E2f7^{Δ/Δ}</i>	<i>E2f7^{Δ/Δ} E2f8^{Δ/Δ}</i>
RBCs (× 10 ⁹ /L)	9.2 ± 0.3	6.9 ± 0.3***	8.6 ± 0.4**	4.3 ± 0.2*** (-)	4.1 ± 0.7*** (-)	7.6 ± 0.3*** (-)	8.6 ± 0.7*
Hemoglobin (g/dL)	14.7 ± 0.8	11.9 ± 0.6***	14.4 ± 0.4	8.0 ± 0.2*** (-)	8.6 ± 0.7*** (-)	13.0 ± 0.8** (-)	14.4 ± 0.4
Hematocrit (%)	41.4 ± 1.8	33.3 ± 2.4***	39.4 ± 3.5	24.5 ± 1.2*** (-)	23.7 ± 3.3*** (-)	37.9 ± 2.5** (-)	38.7 ± 2.6*
MCV (fL)	44.8 ± 1.7	48.8 ± 2.9**	44.5 ± 1.0	57.6 ± 2.4*** (-)	58.0 ± 2.7*** (-)	50.1 ± 1.8***	45.0 ± 1.3
MCH (fg)	15.9 ± 1.0	17.4 ± 0.8**	15.0 ± 0.8	18.7 ± 0.6*** (-)	21.2 ± 2.2*** (-)	17.2 ± 0.4*	16.7 ± 0.9
MCHC (g/dL)	35.5 ± 1.3	35.7 ± 2.4	35.0 ± 2.3	32.6 ± 1.3** (-)	36.5 ± 2.6	34.3 ± 1.1	37.1 ± 1.4*
RDW (%)	17.7 ± 2.5	21.3 ± 2.2**	17.2 ± 1.1	25.3 ± 3.2*** (-)	27.1 ± 1.3*** (-)	ND	ND
Reticulocyte (× 10 ⁹ /L)	2.1 ± 0.2	3.2 ± 0.6*	2.6 ± 0.4	9.5 ± 1.5*** (-)	8.8 ± 0.6*** (-)	ND	ND
nRBC (per 5000 RBCs)	0 ± 0	0 ± 0	0 ± 0	4.4 ± 0.9** (-)	ND	ND	ND
Erythropoietin (pg/mL)	185.4 ± 16	468.6 ± 7***	ND	1944.2 ± 143*** (-)	1986.0 ± 173*** (-)	ND	ND
Total bilirubin (mg/dL)	0.4 ± 0	0.3 ± 0	ND	0.8 ± 0.1	1.2 ± 0.2	ND	ND
Unconjugated bilirubin (mg/dL)	0.3 ± 0	0.3 ± 0	ND	0.7 ± 0.1	1.0 ± 0.1	ND	ND

Shown are mean values ± SD. n ≥ 3 per genotypic groups except for total bilirubin and unconjugated bilirubin assays (n = 2). Asterisks represent statistical comparisons to *Rb^{LoxP/LoxP}* mice, whereas asterisks in parentheses represent statistical comparisons to *Rb^{Δ/Δ}* mice.

nRBC indicates nucleated RBC; RDW, red cell distribution width; and ND, not determined.

*P < .05.

**P < .01.

***P < .001.

erythropoiesis. Consistent with this notion, concomitant inactivation of *E2f7* did not worsen the severe anemia in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice substantially (Table 1). In addition to reduced RBCs, hemoglobin, and hematocrit, *Rb^{Δ/Δ}* mice also displayed increased mean cell volume and mean cell hemoglobin, which were further increased in the *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice. Interestingly, a significant reduction of mean cell hemoglobin concentrations was also observed in the *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice (Table 1).

As described previously,^{7,10} inactivation of Rb in HSCs led to moderate splenomegaly (Figure 1A). Although there were no significant increases of spleen weights in the *E2f8^{Δ/Δ}* mice, the spleens of *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice were enormous, being increased by approximately 50-fold compared with those of control mice (Figure 1C). Conversely, *Rb^{Δ/Δ}E2f7^{Δ/Δ}* mice had spleens similar in size to the *Rb^{Δ/Δ}* mice (Figure 1C), further supporting a predominant role of *E2f8* in mediating Rb function in erythropoiesis. As expected, the numbers of splenocytes in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice were also increased dramatically (Figure 1D). However, there were no significant differences in BM cellularity in any of the genotypic groups (supplemental Figure 2).

Histologic examination of H&E-stained spleen sections indicated that, unlike spleens from control mice and *Rb^{Δ/Δ}* mice, which consisted of red pulp and white pulp, spleens from *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice lacked white pulp and were almost completely filled with erythroid progenitors (Figure 1B), suggesting the presence of massive extramedullary erythropoiesis. Flow cytometric analyses revealed enormous increases in early erythroid cells (CD71⁺Ter119⁺) and decreases in late erythroid cells (CD71⁻Ter119⁺) in the spleens of *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice (Figure 1E-G). Consistent with previous studies,^{7,10} *Rb^{Δ/Δ}* mice showed a decrease in erythroid cells (both early and late) in the BM (Figure 1H-J). Interestingly, although there was no significant difference in the number of total erythroid cells in the BM of *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice compared with those from control mice, there was a decrease in late erythroid cells and an increase in early erythroid cells (Figure 1H-J). Because there was a substantial myeloid expansion in the BM of the *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice (supplemental Figure 4), the increased percentage of early erythroid cells in the BM, coupled with the substantial increases of early erythroid cells in the spleen, suggests active erythroid regeneration in response to the anemia. Consistent with this notion, *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice had a 10-fold increase in erythropoietin levels, a 4.5-fold increase in circulating

reticulocytes, and increased nucleated RBCs, anisocytosis (increased RBC distribution width), and polychromasia in their peripheral blood (supplemental Figure 5 and Table 1). In addition, BrdU incorporation analysis of early erythroid cells of spleens and BM revealed significantly higher percentages of S-phase cells and significantly lower percentages of G₁-phase cells in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice than in control or *Rb^{Δ/Δ}* mice (Figure 1K-L). These data suggest that early erythroid cells in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice were highly proliferating. Conversely, early erythroid cells from both spleens and BM showed similar levels of apoptosis among the different genotypic groups (supplemental Figure 3), suggesting that the expansion of early erythroid cells likely resulted from increased proliferation instead of decreased apoptosis.

Impaired erythroid differentiation in *Rb^{Δ/Δ}* mice and *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice

Considering the important role of Rb in erythropoiesis^{6,12} and the severe anemia in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice, we investigated whether ineffective erythropoiesis can contribute to the severe anemia using a recently established erythroid-staging system³³ to differentiate Ter119⁺ cells into 5 subpopulations sorted based on Ter119, CD71, and cell size (forward scatter). Similar to the previous study,³³ our sorted subpopulations represent erythroid cells at different developmental stages with reasonably good purities (supplemental Figure 6). Using this system, we found that the E3 and E2 subpopulations representing late-stage erythroid precursors were increased significantly in *Rb^{Δ/Δ}* mice and further enriched in those from *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice (Figure 1M-P and supplemental Figure 6). In contrast, subpopulation E4 (predominantly reticulocytes) and R (almost exclusively RBCs) were reduced significantly in both the BM and spleens from *Rb^{Δ/Δ}* mice and further reduced in those from *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice. The significant enrichment of late-stage erythroid precursors and the significant reduction of reticulocytes and RBCs in both spleens and BM support the idea that *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice suffer from defects in erythroid terminal differentiation, leading to marked ineffective erythropoiesis that significantly contributes to the severe anemia. Interestingly, unlike in humans, where ineffective erythropoiesis is often associated with elevated apoptosis, erythroid precursors in the *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice appeared to have normal apoptosis rates (supplemental Figure 3), reminiscent of the *Rb*-knockout mouse model in which ineffective




Figure 1. *Mx1-Cre*-mediated inactivation of *Rb* and *E2f8* in HSCs results in enhanced but ineffective erythropoiesis. (A) Representative pictures of whole spleens of mice with the indicated genotypes. (B) Representative pictures of H&E-stained sections of spleens from mice with indicated genotypes. The scale bar indicates 100 μm. (C-D) Spleen weights (C) and spleen cell numbers (D) of mice with the indicated genotypes. (E-J) Flow cytometric analysis for total erythroid cells, late erythroid cells, and early erythroid cells in spleens (E-G) and BM (H-J). (K-L) Cell-cycle distributions based on a BrdU incorporation assay for early erythroid cells (CD71⁺Ter119⁺) in spleens (K) and BM (L) from mice with the indicated genotypes (n = 3 mice/genotypic group). (M-P) Erythroid staging by flow cytometric analysis of Ter119⁺ BM (M-N) and spleen cells (O-P) sorted by CD71 and cell size (forward scatter, FSC). (M,O) Representative flow cytometric profiles. (N,P) Percentages of different erythroid subpopulations were normalized to total Ter119⁺ cells (n = 4 mice/genotypic group). In all figures, asterisks indicate statistical comparisons with control (*Rb^{LoxP/LoxP}*) mice and asterisks in parentheses indicate statistical comparisons with *Rb*-knockout mice as follows: **P* < .05; ***P* < .01; and ****P* < .001.

erythropoiesis is present without measurable changes in apoptosis rates.¹²

Hemolysis in *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice

To evaluate whether *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice experience intravascular hemolysis, we performed Prussian blue staining on paraffin-embedded tissue sections to assess iron deposits. As expected, spleen sections from mice with all genotypic groups contained Prussian blue–positive cells representing macrophages and reflecting baseline hemolysis (Figure 2A). There was no obvious Prussian blue staining in livers or kidneys from control, *Rb*^{ΔΔ}, or *E2f8*^{ΔΔ} mice. In sharp contrast, *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice displayed marked staining in renal proximal tubular cells, moderate staining in liver Kupffer cells, and weak staining in hepatocytes surrounding hematopoietic foci. Bilirubin, particularly unconjugated bilirubin, was moderately increased in the sera of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice and *Rb*^{ΔΔ}*E2f8*^{ΔΔ}*E2f8*^{ΔΔ} mice compared with those of control mice or *Rb*^{ΔΔ} mice (Table 1), suggesting the presence of mild hemolysis. Consistent with this notion, peripheral RBCs from *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice had a 4.5-fold increase in circulating reticulocytes, moderately shortened life spans (half-lives being reduced from approximately 16 days to approximately 11 days), slightly reduced deformability, and moderately increased osmotic fragility (Figure 2B-E, supplemental Figure 7, and Table 1). Morphologically, both spherocytes and echinocytes were increased in these mice (Figure 2F-G). These data suggest that inactivation of *Rb* and *E2f8* synergizes to trigger mild hemolysis.

In addition to a synergistic increase in reticulocytes (CD71⁺TO⁺) from the peripheral blood of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice compared with those of *Rb*^{ΔΔ} mice and *E2f8*^{ΔΔ} mice, we also observed a synergistic increase in the CD71⁺TO⁻ population, which represents enucleated RBCs with high levels of CD71 (Figure 2H). Because down-regulation of the transferrin receptor (CD71) is a critical step for erythrocyte membrane remodeling as reticulocytes mature to enucleated RBCs,³⁷ these data suggest compromised membrane remodeling process in the *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice. Interestingly, levels of 6 discernible major membrane proteins seemed to be comparable among ghosts collected from various genotypic groups, although 2 unknown bands appeared to be more intense in the *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice (supplemental Figure 6).

Depletion of HSCs/hematopoietic progenitor cells in the BM of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice

As observed in many anemic mouse models in which the spleen is the major source of increased RBC production because of limited capacity of BM expansion, HSCs and progenitors are significantly reduced in the BM and increased in the spleens of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice (Figure 3A-B). Consistent with these data, significant decreases of BM in vivo, day 8 and 12 CFU-S, and expansions of lineage-committed progenitors (CFU-GEMM, CFU-GM, and BFU-E) in the spleens were also observed in these mice (Figure 3C-G). Consistent with myeloproliferation and expansions of early erythroid cells in the BM (Figure 1 and supplemental Figure 4), both the BFU-E and CFU-GM populations were significantly increased in the BM of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice (Figure 3H). These data suggest that in *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice, HSCs in the BM are mobilized to the spleen to differentiate into lineage-committed progenitors in response to severe anemia.


Erythroid-intrinsic role of *Rb* and *E2f8* in maintaining normal erythropoiesis and preventing hemolysis

Our data show that inactivation of *E2f8* synergizes with *Rb* deficiency to induce severe anemia. To determine whether the role of *Rb* and *E2f8* in regulating erythropoiesis is cell autonomous, we transplanted BM cells into lethally irradiated wild-type mice. Because inactivation of *Rb* and *E2f8* causes HSC depletion in the BM, lethally irradiated mice receiving the standard number (2×10^6) of *Rb*^{ΔΔ}*E2f8*^{ΔΔ} BM cells failed to survive. We overcame this problem by injecting either more *Rb*^{ΔΔ}*E2f8*^{ΔΔ} donor cells ($6-10 \times 10^6$), or the standard number (2×10^6) of *Mx1-Cre*^{+/-}*Rb*^{LoxP/LoxP}*E2f8*^{LoxP/LoxP} BM cells followed by poly(I:C) injection 35 days after transplantation to inactivate *Rb* and *E2f8*. Both approaches yielded similar results. Specifically, mice receiving *Rb*^{ΔΔ}*E2f8*^{ΔΔ} BM cells recapitulated all erythropoietic defects observed in mice with *Mx1-Cre*–mediated inactivation of *Rb* and *E2f8*, including severe anemia, profound splenomegaly, and enormous expansion of early erythroid cells (Figure 4). These data suggest that the functional interaction of *Rb* and *E2f8* in erythropoiesis is cell autonomous. In addition, inactivation of *Rb* and *E2f8* specifically in the erythroid lineage by the *EpoR-GFP**Cre* allele²⁹ also recapitulated the synergy of *Rb* and *E2f8* loss in triggering severe anemia that resulted from both ineffective erythropoiesis and hemolysis (Figure 5A-H and supplemental Figure 9). These data support the idea that the collaborative role of *Rb* and *E2f8* in maintaining normal erythropoiesis and preventing hemolysis is erythroid intrinsic.

Discussion

Using conditional knockout mouse models, in the present study, we uncovered a potent and erythroid-intrinsic synergy of inactivation of *E2f8* and *Rb* to trigger severe anemia. Our data represent the first evidence that a specific E2F family member that does not have a consensus pocket-protein-binding domain can functionally interact with a pocket protein in vivo. We found that although deletion of *Rb* or *E2f8* in HSCs leads to mild erythropoietic defects (for *Rb*) or almost no defect (for *E2f8*), concomitant inactivation of both genes exacerbated the erythropoietic defect resulted from *Rb* deficiency significantly, leading to severe anemia. We also showed that the severe anemia in the *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice resulted from both profound ineffective erythropoiesis and mild hemolysis. Whereas ineffective erythropoiesis is already present in *Rb*^{ΔΔ} mice but is much more profound in *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice, hemolysis is only present when both *Rb* and *E2f8* are inactivated. *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice are responsive to the anemia, as evidenced by the enhanced but still ineffective erythropoiesis and increased circulating reticulocyte counts. However, the underlying ineffective erythropoiesis and persistent mild hemolysis still render the mice severely anemic. Therefore, the steady reticulocytosis observed in the *Rb*^{ΔΔ}*E2f8*^{ΔΔ} mice (Table 1) is not an indicator of effective erythropoiesis, but rather is a reflection of regenerative erythropoiesis, the premature release of immature reticulocytes to the peripheral circulation to compensate for the severe anemia, and the longer time for such reticulocytes to mature into RBCs in the peripheral circulation.

During their life span, RBCs face strong circulatory shearing forces through circulation and microcirculation. Therefore, they must be flexible to pass safely through blood vessels and capillaries. The deformability and durability of RBCs are largely controlled by membrane skeletal proteins. Mutations causing defects in one or more membrane skeletal proteins have






Figure 3. Depletion of HSCs in the BM of *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice. (A-B) The absolute numbers of phenotypic stem cells (Lin⁻c-kit⁺Sca-1⁺ [LKS⁺]), progenitors (Lin⁻c-kit⁺Sca-1⁻ [LKS⁻]), and long-term stem cells (Flk2⁻Lin⁻c-kit⁺Sca-1⁺) in the BM (A) and spleens (B) were estimated by flow cytometric analysis. Values above each bar in panel B represent the fold increases compared with control mice. (C-F) Photographs (C-D) and numbers (E-F) of CFU-S colonies from mice with the indicated genotypes. (G-H) Numbers of CFU-GEMM, CFU-GM, and BFU-E in the spleens (G) and BM (H) of mice with the indicated genotypes.

often been found in patients with hemolytic anemia.³⁸ In the last decade, many mouse models for hemolytic anemia with spontaneous mutations or targeted disruptions of genes encoding membrane skeletal proteins have been generated. Data from these models further support the important role of erythrocyte membrane skeletal proteins.³⁸ Hemolysis may also arise from impaired glucose metabolism, hemoglobin synthesis, or defective erythrocyte membrane permeability.³⁹⁻⁴² However, it re-

mains largely unknown how these critical proteins are regulated. In the present study, we have shown that inactivation of *Rb* and *E2f8* in erythroid cells synergizes to trigger hemolysis (Figure 2). Increased osmotic fragility, impaired deformability, and abnormal morphologies of *Rb^{Δ/Δ}E2f8^{Δ/Δ}* erythrocytes suggest that the increased hemolysis is possibly because of impaired RBC membrane integrity. In addition, defective down-regulation of CD71 was also found in the *Rb^{Δ/Δ}E2f8^{Δ/Δ}* reticulocytes,




Figure 4. Lethally irradiated mice harboring HSCs deficient for *Rb* and *E2f8* suffer from severe anemia. (A-D) Peripheral blood RBC numbers (A), hemoglobin (B), hematocrit (C), and spleen weights (D) of mice with the indicated genotypes. (E-J) Flow cytometric analysis of spleens (E-F) and BM (G-H) using lineage-specific cell-surface markers. Data labeled "post" were from mice that received BM donor cells harvested from mice that were injected with poly(I:C), whereas data labeled "+35" were from mice that received BM donor cells harvested from mice that had not been injected with poly(I:C). In the latter case, recipient mice were injected with poly(I:C) 35 days after transplantation.

suggesting a membrane-remodeling defect during the reticulocyte maturation process. Many factors can contribute to erythrocyte membrane integrity, such as depleted cytoskeletal membrane proteins, abnormal partitioning of such proteins into various protein complexes, or defective membrane physiology such as a sodium leak or other ion channel defects. Given the important role of Rb in the oxidative stress response⁴ and mitochondrial biogenesis,¹² increased oxidative stress and/or abnormal mitochondrial activities may also be the cause of hemolysis in *Rb^{Δ/Δ}E2f8^{Δ/Δ}* mice.

As the 2 recently identified E2F transcriptional repressors, E2F7 and E2F8 share several unique features that distinguish them from other members of the E2F family.¹⁸ Consistent with their structural and biochemical similarities, E2F7 and E2F8 are functionally redundant during early mouse development, because *E2f7^{-/-}E2f8^{-/-}* embryos die in utero even though *E2f7^{-/-}* or *E2f8^{-/-}* mice are viable.³¹ In the present study, we identified a unique synergy between loss of *E2f8* (but not *E2f7*) and *Rb* deficiency to induce severe anemia. It will be interesting to know whether the difference between E2F7 and E2F8 in mediating Rb function is because of their differential promoter regulations or their different protein identities. Because E2F8 lacks a Rb pocket-protein-binding domain,¹⁸ its functional interaction with Rb is likely independent of pocket-protein binding.

Considering the corepressor role of Rb and the transcriptional repressor role of E2F8, we speculate that the potent synergy is most likely because of transcriptional deregulation or derepression of critical E2F targets gene(s) involved in maintaining normal erythropoiesis and in preventing hemolysis. Whereas the precise molecular mechanism underlying the synergy remains to be delineated, we propose 2 possible molecular mechanisms to explain how E2F8 can interact functionally with Rb to prevent target gene deregulation and severe anemia. The first possibility is the direct and overlapping down-regulation of critical targets by Rb and E2F8. In this context, Rb and E2F8 may repress either the same or different critical targets that are redundant to prevent anemia. As a transcriptional corepressor, in the absence of E2F8, Rb can impose active transcriptional repression of target genes by its association with repressor complexes. Conversely, in the absence of Rb, as a transcriptional repressor, E2F8 can maintain active repression. In the absence of both genes, however, critical target(s) would be deregulated. The fact that Rb can interact with various hematopoietic/erythroid transcription factors, such as GATA-1, PU1, and EKLF,⁴³⁻⁴⁵ suggests that Rb may exert its corepressor function by repressing critical targets for erythropoiesis.

The second possibility is the involvement of an activator E2F (E2F1-3) that regulates target genes important for maintaining




Figure 5. *EpoR-GFP-Cre*-mediated inactivation of *Rb* and *E2f8* in the erythroid compartment results in severe anemia and enhanced but ineffective erythropoiesis. (A-D) Peripheral blood RBC numbers (A), hemoglobin (B), hematocrit (C), and spleen weights (D) of mice with the indicated genotypes. (E-K) Flow cytometric analysis of spleens (E-F) and BM (G-K) using lineage-specific cell-surface markers. (I-L) Erythroid staging by flow cytometric analysis of Ter119⁺ BM (I-J) and spleen cells (K-L) sorted by CD71 and cell size (forward scatter, FSC). (I, K) Representative flow cytometric profiles. (J, L) Percentages of different erythroid subpopulations normalized to total Ter119⁺ cells.

normal erythropoiesis and for preventing hemolysis. In this context, Rb can bind to the activator E2F and prevent E2F-mediated transcriptional activation of target genes. As a transcriptional repressor, E2F8 can either repress the activator E2F or compete

with it for E2F-binding sites of target gene promoters. In the absence of Rb, whereas the activator E2F is expected to be free from Rb binding and inhibition, E2F8 can still repress the activator E2F or occupy its E2f-binding sites of target gene promoters to

maintain relatively normal regulation of the target genes. In the absence of E2f8, Rb binding and inhibition of the activator E2F may be sufficient to prevent aberrant activation of E2F target genes. However, in the absence of both genes, the activator E2F can be deregulated, leading to aberrant activation of target genes. The involvement of E2F2 in mediating Rb function in embryonic erythropoiesis²⁸ raises an intriguing possibility that E2F2 is a relevant activator E2F responsible for the synergy in adult erythropoiesis. Consistent with this possibility, E2F2 has been linked functionally to GATA-1 and EKLF, 2 important erythroid transcription factors that are critical for erythroid terminal differentiation^{28,43,44} and that are implicated in hemolysis.^{46,47}

Acknowledgments

The authors thank Drs Gustavo Leone and Alain deBruin for providing *E2f7^{LoxP/LoxP}* and *E2f8^{LoxP/LoxP}* mice before their publication; Drs Ursula Klingmueller and James D. Engel for providing *EpoR-GFP^{Cre}* mice; Dr Anton Berns for providing *Rb^{LoxP/LoxP}* mice; Dr Mohandas Narla for critically reviewing the manuscript; and Drs David Lagunoff, Dianne Pulte, Joseph Bertino, Pranela

Rameshwar, Edwin Deitch, Michael Mathews, Tulin Budak-Alpdogan, Limin Shu, and Dan Li for technical assistance.

This work was supported by grants from the National Institutes of Health, the Leukemia Research Foundation, and the University of Medicine and Dentistry of New Jersey Foundation (to L.W.). T.H. is a postdoctoral fellow of the New Jersey Commission on Cancer Research.

Authorship

Contribution: T.H. designed and performed the experiments and wrote and edited the manuscript; S.G. performed and assisted with the experiments, and edited the manuscript; C.S. assisted with the experiments; C.W. and V.C. designed the experiments and edited the manuscript; and L.W. designed the experiments and wrote and edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Lizhao Wu, New Jersey Medical School–University Hospital Cancer Center, University of Medicine and Dentistry of New Jersey, 205 South Orange Ave, Newark, NJ 07103; e-mail: wuli@umdnj.edu.

References

- Clarke AR, Maandag ER, van Rooij M, et al. Requirement for a functional Rb-1 gene in murine development. *Nature*. 1992;359(6393):328-330.
- Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. *Nature*. 1992;359(6393):295-300.
- Lee EY, Chang CY, Hu N, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. *Nature*. 1992;359(6393):288-294.
- Macleod KF. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. *Nat Rev Cancer*. 2008;8(10):769-781.
- Walkley CR, Sankaran VG, Orkin SH. Rb and hematopoiesis: stem cells to anemia. *Cell Div*. 2008;3:13.
- Clark AJ, Doyle KM, Humbert PO. Cell-intrinsic requirement for pRb in erythropoiesis. *Blood*. 2004;104(5):1324-1326.
- Daria D, Filippi MD, Knudsen ES, et al. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. *Blood*. 2008;111(4):1894-1902.
- Iavarone A, King ER, Dai XM, Leone G, Stanley ER, Lasorella A. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. *Nature*. 2004;432(7020):1040-1045.
- Spike BT, Dirlam A, Dibling BC, et al. The Rb tumor suppressor is required for stress erythropoiesis. *EMBO J*. 2004;23(21):4319-4329.
- Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. *Cell*. 2007;129(6):1081-1095.
- Wu L, de Bruin A, Saavedra HI, et al. Extra-embryonic function of Rb is essential for embryonic development and viability. *Nature*. 2003;421(6926):942-947.
- Sankaran VG, Orkin SH, Walkley CR. Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. *Genes Dev*. 2008;22(4):463-475.
- Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. *Oncogene*. 2005;24(17):2810-2826.
- Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. *Nat Rev Mol Cell Biol*. 2002;3(1):11-20.
- Dyson N. The regulation of E2F by pRB-family proteins. *Genes Dev*. 1998;12(15):2245-2262.
- Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. *Cell Growth Differ*. 1998;9(8):585-593.
- van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. *Nat Rev Mol Cell Biol*. 2008;9(9):713-724.
- Lammens T, Li J, Leone G, De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. *Trends Cell Biol*. 2009;19(3):111-118.
- Trimarchi JM, Fairchild B, Wen J, Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. *Proc Natl Acad Sci U S A*. 2001;98(4):1519-1524.
- Chong JL, Tsai SY, Sharma N, et al. E2f3a and E2f3b contribute to the control of cell proliferation and mouse development. *Mol Cell Biol*. 2009;29(2):414-424.
- Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD. E2F4 loss suppresses tumorigenesis in Rb mutant mice. *Cancer Cell*. 2002;2(6):463-472.
- Lee EY, Yuan TL, Danielian PS, West JC, Lees JA. E2F4 cooperates with pRB in the development of extra-embryonic tissues. *Dev Biol*. 2009;332(1):104-115.
- Parisi T, Yuan TL, Faust AM, Caron AM, Bronson R, Lees JA. Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues. *Mol Cell Biol*. 2007;27(6):2283-2293.
- Saavedra HI, Wu L, de Bruin A, et al. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. *Cell Growth Differ*. 2002;13(5):215-225.
- Wenzel PL, Wu L, de Bruin A, et al. Rb is critical in a mammalian tissue stem cell population. *Genes Dev*. 2007;21(1):85-97.
- Ziebold U, Lee EY, Bronson RT, Lees JA. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. *Mol Cell Biol*. 2003;23(18):6542-6552.
- Ziebold U, Reza T, Caron A, Lees JA. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. *Genes Dev*. 2001;15(4):386-391.
- Dirlam A, Spike BT, Macleod KF. Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts. *Mol Cell Biol*. 2007;27(24):8713-8728.
- Heinrich AC, Pelanda R, Klingmuller U. A mouse model for visualization and conditional mutations in the erythroid lineage. *Blood*. 2004;104(3):659-666.
- Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. *Science*. 1995;269(5229):1427-1429.
- Li J, Ran C, Li E, et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. *Dev Cell*. 2008;14(1):62-75.
- Vooijs M, te Riele H, van der Valk M, Berns A. Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinoid binding protein-expressing cells. *Oncogene*. 2002;21(30):4635-4645.
- Kalfa TA, Pushkaran S, Zhang X, et al. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. *Haematologica*. 2010;95(1):27-35.
- Spolarics Z, Condon MR, Siddiqi M, Machiedo GW, Deitch EA. Red blood cell dysfunction in septic glucose-6-phosphate dehydrogenase-deficient mice. *Am J Physiol Heart Circ Physiol*. 2004;286(6):H2118-2126.
- Chen H, Khan AA, Liu F, et al. Combined deletion of mouse dematin-headpiece and beta-actin exerts a novel effect on the spectrin-actin junctions leading to erythrocyte fragility and hemolytic anemia. *J Biol Chem*. 2007;282(6):4124-4135.
- Kalfa TA, Pushkaran S, Mohandas N, et al. Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton. *Blood*. 2006;108(12):3637-3645.
- Liu J, Guo X, Mohandas N, Chasis JA, An X. Membrane remodeling during reticulocyte maturation. *Blood*. 2010;115(10):2021-2027.
- McMullin MF. The molecular basis of disorders of the red cell membrane. *J Clin Pathol*. 1999;52(4):245-248.

39. De Franceschi L, Rivera A, Fleming MD, et al. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. *Blood*. 2005;106(4):1454-1459.
40. McMullin MF. The molecular basis of disorders of red cell enzymes. *J Clin Pathol*. 1999;52(4):241-244.
41. Peters LL, Jindel HK, Gwynn B, et al. Mild spherocytosis and altered red cell ion transport in protein 4.2-null mice. *J Clin Invest*. 1999;103(11):1527-1537.
42. Rouyer-Fessard P, Leroy-Viard K, Domenget C, Mrad A, Beuzard Y. Mouse beta thalassemia, a model for the membrane defects of erythrocytes in the human disease. *J Biol Chem*. 1990;265(33):20247-20251.
43. Kadri Z, Shimizu R, Ohneda O, et al. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. *PLoS Biol*. 2009;7(6):e1000123.
44. Rektman N, Choe KS, Matushansky I, Murray S, Stopka T, Skoultchi AI. PU. 1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. *Mol Cell Biol*. 2003;23(21):7460-7474.
45. Tallack MR, Keys JR, Humbert PO, Perkins AC. EKLF/KLF1 controls cell cycle entry via direct regulation of E2f2. *J Biol Chem*. 2009;284(31):20966-20974.
46. Nakano M, Ohneda K, Yamamoto-Mukai H, et al. Transgenic over-expression of GATA-1 mutant lacking N-finger domain causes hemolytic syndrome in mouse erythroid cells. *Genes Cells*. 2005;10(1):47-62.
47. Perkins AC, Peterson KR, Stamatoyannopoulos G, Witkowska HE, Orkin SH. Fetal expression of a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLF null mouse embryos. *Blood*. 2000;95(5):1827-1833.